Why Moderna Trounced the Market on Thursday

Motley Fool2021-09-03

The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened Hardly for the first time since the rise of the COVID delta variant, star ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Inthebag
2021-09-04
Inthebag
Lol
cynn
2021-09-03
cynn
Ok
23a2d027
2021-09-03
23a2d027
oh
- 4872be6:
  Comment
- Huathk:
  Gd
Angsana
2021-09-03
Angsana
Like
- nana99:
  Okay
- Angsana:
  ok
wintomoon
2021-09-03
wintomoon
Wow
Kc48
2021-09-03
Kc48
Wow
- wintomoon:
  Wow

发表看法

130

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1106687082?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-03 08:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106687082","market":"us","top_or_hot":-1,"title":"Why Moderna Trounced the Market on Thursday","media":"Motley Fool","content":"<div>\nThe company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star ...\n\n<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Trounced the Market on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Trounced the Market on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 08:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star ...\n\n<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/","article_id":"1106687082","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106687082","pubTimestamp":1630629335,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booste","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"为什么莫德纳在周四大败市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna(NASDAQ:MRNA)well outpaced the S&P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.\nSo what\nThe main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).\nSpecifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.\n\"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.\nLike the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.\nNow what\nWhile Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":815587755,"gmtCreate":1630695287777,"gmtModify":1631888464057,"author":{"id":"4088170120999190","authorId":"4088170120999190","name":"Inthebag","avatar":"https://static.tigerbbs.com/532287c1d6af7ef8ff3a2ac9ae2177c1","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4088170120999190","authorIdStr":"4088170120999190"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815587755","repostId":1106687082,"repostType":2,"repost":{"id":"1106687082","kind":"news","pubTimestamp":1630629335,"share":"https://www.laohu8.com/m/news/1106687082?lang=zh_CN&edition=full","pubTime":"2021-09-03 08:35","market":"us","language":"en","title":"Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106687082","media":"Motley Fool","summary":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booste","content":" The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-03 08:35\n\n</h4>\n</header>\n<article>\n The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106687082","content_text":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna(NASDAQ:MRNA)well outpaced the S&P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.\nSo what\nThe main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).\nSpecifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.\n\"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.\nLike the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.\nNow what\nWhile Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815659330,"gmtCreate":1630677020820,"gmtModify":1632467478469,"author":{"id":"4091975549439940","authorId":"4091975549439940","name":"cynn","avatar":"https://static.tigerbbs.com/d45b68148695cb02b6620353f88f7880","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"4091975549439940","authorIdStr":"4091975549439940"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815659330","repostId":1106687082,"repostType":2,"repost":{"id":"1106687082","kind":"news","pubTimestamp":1630629335,"share":"https://www.laohu8.com/m/news/1106687082?lang=zh_CN&edition=full","pubTime":"2021-09-03 08:35","market":"us","language":"en","title":"Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106687082","media":"Motley Fool","summary":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booste","content":" The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-03 08:35\n\n</h4>\n</header>\n<article>\n The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106687082","content_text":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna(NASDAQ:MRNA)well outpaced the S&P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.\nSo what\nThe main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).\nSpecifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.\n\"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.\nLike the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.\nNow what\nWhile Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815024253,"gmtCreate":1630631485072,"gmtModify":1631893384755,"author":{"id":"3572502301692301","authorId":"3572502301692301","name":"23a2d027","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3572502301692301","authorIdStr":"3572502301692301"},"htmlText":"oh","listText":"oh","text":"oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/815024253","repostId":1106687082,"repostType":4,"repost":{"id":"1106687082","kind":"news","pubTimestamp":1630629335,"share":"https://www.laohu8.com/m/news/1106687082?lang=zh_CN&edition=full","pubTime":"2021-09-03 08:35","market":"us","language":"en","title":"Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106687082","media":"Motley Fool","summary":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booste","content":" The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-03 08:35\n\n</h4>\n</header>\n<article>\n The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106687082","content_text":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna(NASDAQ:MRNA)well outpaced the S&P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.\nSo what\nThe main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).\nSpecifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.\n\"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.\nLike the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.\nNow what\nWhile Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5737512,"gmtCreate":1630634298097,"gmtModify":1635132230390,"authorId":3583641915640836,"author":{"id":3583641915640836,"idStr":"3583641915640836","authorId":3583641915640836,"name":"4872be6","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815024253,"type":1,"supId":0,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"},{"id":5737941,"gmtCreate":1630636414387,"gmtModify":1635132194596,"authorId":3573472992263411,"author":{"id":3573472992263411,"idStr":"3573472992263411","authorId":3573472992263411,"name":"Huathk","avatar":"https://static.tigerbbs.com/43c7168c646d9ea6805194ed0003f1cc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815024253,"type":1,"supId":5737512,"prevId":0,"content":"Gd","text":"Gd","html":"Gd"}],"langContent":"EN"},{"id":815028329,"gmtCreate":1630631266661,"gmtModify":1632469383873,"author":{"id":"3575326435298567","authorId":"3575326435298567","name":"Angsana","avatar":"https://static.tigerbbs.com/3c8492153d7059ec1aa704a1bd541c14","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575326435298567","authorIdStr":"3575326435298567"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/815028329","repostId":1106687082,"repostType":4,"repost":{"id":"1106687082","kind":"news","pubTimestamp":1630629335,"share":"https://www.laohu8.com/m/news/1106687082?lang=zh_CN&edition=full","pubTime":"2021-09-03 08:35","market":"us","language":"en","title":"Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106687082","media":"Motley Fool","summary":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booste","content":" The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-03 08:35\n\n</h4>\n</header>\n<article>\n The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106687082","content_text":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna(NASDAQ:MRNA)well outpaced the S&P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.\nSo what\nThe main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).\nSpecifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.\n\"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.\nLike the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.\nNow what\nWhile Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5736770,"gmtCreate":1630631431544,"gmtModify":1635132296470,"authorId":3578649684330150,"author":{"id":3578649684330150,"idStr":"3578649684330150","authorId":3578649684330150,"name":"nana99","avatar":"https://static.tigerbbs.com/8e1d85c2911a74d975df652e54cba9a9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815028329,"type":1,"supId":0,"prevId":0,"content":"Okay","text":"Okay","html":"Okay"},{"id":5739111,"gmtCreate":1630643983677,"gmtModify":1635132097521,"authorId":3575326435298567,"author":{"id":3575326435298567,"idStr":"3575326435298567","authorId":3575326435298567,"name":"Angsana","avatar":"https://static.tigerbbs.com/3c8492153d7059ec1aa704a1bd541c14","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815028329,"type":1,"supId":5736770,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":815065859,"gmtCreate":1630630891671,"gmtModify":1631893628640,"author":{"id":"4089511636620760","authorId":"4089511636620760","name":"wintomoon","avatar":"https://static.tigerbbs.com/ae37c5a6c50ab9921f20d4efbd4b6710","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4089511636620760","authorIdStr":"4089511636620760"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815065859","repostId":1106687082,"repostType":4,"repost":{"id":"1106687082","kind":"news","pubTimestamp":1630629335,"share":"https://www.laohu8.com/m/news/1106687082?lang=zh_CN&edition=full","pubTime":"2021-09-03 08:35","market":"us","language":"en","title":"Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106687082","media":"Motley Fool","summary":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booste","content":" The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-03 08:35\n\n</h4>\n</header>\n<article>\n The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106687082","content_text":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna(NASDAQ:MRNA)well outpaced the S&P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.\nSo what\nThe main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).\nSpecifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.\n\"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.\nLike the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.\nNow what\nWhile Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815089570,"gmtCreate":1630630172590,"gmtModify":1632469539993,"author":{"id":"3582943967323128","authorId":"3582943967323128","name":"Kc48","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3582943967323128","authorIdStr":"3582943967323128"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815089570","repostId":1106687082,"repostType":4,"repost":{"id":"1106687082","kind":"news","pubTimestamp":1630629335,"share":"https://www.laohu8.com/m/news/1106687082?lang=zh_CN&edition=full","pubTime":"2021-09-03 08:35","market":"us","language":"en","title":"Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106687082","media":"Motley Fool","summary":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booste","content":" The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Trounced the Market on Thursday<blockquote>为什么Moderna周四跑赢市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-03 08:35\n\n</h4>\n</header>\n<article>\n The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster. What happened<blockquote>该公司显然决心为其冠状病毒疫苗加强剂赢得监管授权。发生了什么</blockquote> Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock&nbsp;Moderna(NASDAQ:MRNA)well outpaced the&nbsp;S&amp;P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.<blockquote>自新冠疫情德尔塔变异毒株上涨以来，明星冠状病毒股票几乎不是第一次现代（纳斯达克：MRNA）远远超过了标普500周四指数。由于积极的消息（如果不是令人震惊的话），该生物技术公司的股票当天收盘涨幅略低于2%，而该指数则略有改善。</blockquote> So what<blockquote>那又怎样</blockquote> The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).<blockquote>过去一天，Moderna的主要股票变动新闻似乎是其向美国食品和药物管理局(FDA)提交的最新文件。</blockquote> Specifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.<blockquote>具体来说，TheBiotech在周三盘后提交了其mRNA-1273冠状病毒疫苗加强剂量的初步数据。它补充说，这样做的目标是在几天内与世界各地的其他监管机构重复这一壮举。这份名单包括欧洲药品管理局(EMA)，它覆盖了庞大的27个国家的欧盟。</blockquote> \"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.<blockquote>Moderna援引其首席执行官Stéphane Bancel的话说：“我们将继续生成数据并透明地共享，以支持政府和监管机构就未来的疫苗接种策略做出循证决策。”</blockquote> Like the Comirnaty coronavirus jab developed by&nbsp;Pfizer&nbsp;and&nbsp;BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.<blockquote>就像Comirnaty冠状病毒疫苗一样辉瑞和BioNTech，mRNA-1273是一种两针疫苗。到目前为止，前者是唯一一种在美国获得FDA完全批准的冠状病毒疫苗，尽管mRNA-1273的点头可能不会太晚。</blockquote> Now what<blockquote>现在怎么办</blockquote> While Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.<blockquote>虽然Moderna向FDA提交的加强剂和计划的国际申请完全在投资者的意料之中，但它们提醒我们，该公司在冠状病毒疫苗山顶附近仍然占据着强大的地位。因此，我们可以预计Moderna在未来几天、几周甚至几个月内会出现更多股票走势头条新闻。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/02/why-moderna-trounced-the-market-on-thursday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106687082","content_text":"The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.\n\nWhat happened\nHardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna(NASDAQ:MRNA)well outpaced the S&P 500index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.\nSo what\nThe main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).\nSpecifically, thebiotechfiled the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.\n\"We will continue to generate data and transparently share to support governments and regulators as they make evidence-based decisions regarding future vaccination strategies,\" Moderna quoted its CEO Stéphane Bancel as saying.\nLike the Comirnaty coronavirus jab developed by Pfizer and BioNTech, mRNA-1273 is a two-shot vaccine. So far the former is the only coronavirus vaccine with full FDA approval in the U.S., although it's likely mRNA-1273's nod isn't too far behind.\nNow what\nWhile Moderna's FDA submission and planned international filings for the booster were entirely expected by investors, they serve to remind us of the company's still-powerful position near the top of the coronavirus vaccine hill. As such, we can expect more stock-moving headlines for Moderna in the days, weeks, and probably months to come.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5736620,"gmtCreate":1630630852729,"gmtModify":1635132310339,"authorId":4089511636620760,"author":{"id":4089511636620760,"idStr":"4089511636620760","authorId":4089511636620760,"name":"wintomoon","avatar":"https://static.tigerbbs.com/ae37c5a6c50ab9921f20d4efbd4b6710","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815089570,"type":1,"supId":0,"prevId":0,"content":"Wow","text":"Wow","html":"Wow"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":130,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106687082","isCrawlerRequest":true}